Kiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $30.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective upped by Evercore ISI from $25.00 to $30.00 in a research report released on Wednesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Other research analysts have also issued research reports about the stock. Wedbush reaffirmed an outperform rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, April 23rd. TheStreet raised shares of Kiniksa Pharmaceuticals from a d+ rating to a c rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $17.88 on Wednesday. The company’s 50 day simple moving average is $19.23 and its 200 day simple moving average is $18.01. Kiniksa Pharmaceuticals has a fifty-two week low of $10.65 and a fifty-two week high of $22.09. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 162.56, a PEG ratio of 5.59 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. The firm had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. During the same period in the previous year, the business earned ($0.18) EPS. The firm’s revenue was up 65.4% compared to the same quarter last year. As a group, analysts predict that Kiniksa Pharmaceuticals will post -0.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sanj K. Patel sold 5,582 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the transaction, the chief executive officer now directly owns 65,012 shares in the company, valued at $1,365,252. The sale was disclosed in a filing with the SEC, which is available through this link. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 12,742 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the transaction, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Sanj K. Patel sold 5,582 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the completion of the transaction, the chief executive officer now owns 65,012 shares in the company, valued at $1,365,252. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,109 shares of company stock worth $709,929. Insiders own 54.23% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Granahan Investment Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 35.2% in the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock valued at $12,671,000 after purchasing an additional 188,174 shares during the last quarter. Parkman Healthcare Partners LLC increased its position in Kiniksa Pharmaceuticals by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 615,693 shares of the company’s stock worth $10,799,000 after acquiring an additional 105,883 shares during the period. Altitude Crest Partners Inc. bought a new position in Kiniksa Pharmaceuticals during the fourth quarter worth about $7,999,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Kiniksa Pharmaceuticals by 59.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 256,932 shares of the company’s stock worth $4,463,000 after acquiring an additional 96,288 shares during the period. Finally, Peregrine Capital Management LLC bought a new position in Kiniksa Pharmaceuticals during the first quarter worth about $4,657,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.